Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32

Molecular Carcinogenesis

Volumn 24, Issue 4, 1999, Pages 300-304

  Mendiola, Marta ^a   Bello, M Josefa ^a   Alonso, Javier ^a,b   Leone, Paola E ^a,f   Vaquero, Jesus ^c   Sarasa, Jose L ^d   Kusak, M Elena ^e   De Campos, Jose M ^e   Pestaña, Angel ^a   Rey, Juan A ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^e HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^f PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

Author keywords

1p deletion mapping; Allelic losses; hRAD54; Meningiomas; Tumor progression

Indexed keywords

DNA;

ALLELE; AMINO ACID SEQUENCE; ARTICLE; DELETION MUTANT; DNA RECOMBINATION; DNA REPAIR; DNA SEQUENCE; GENE DELETION; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MENINGIOMA; PATHOGENESIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

3' UNTRANSLATED REGIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 1; DNA MUTATIONAL ANALYSIS; DNA REPAIR; DNA, NEOPLASM; EXONS; FEMALE; GENE DELETION; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POINT MUTATION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0032925350     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199904)24:4<300::AID-MC8>3.0.CO;2-G     Document Type: Article

References (35)

1. Russel DS, Rubinstein LJ. Pathology of the nervous system. Baltimore: Williams and Wilkins; 1990.
2. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the nervous system. WHO International Histological Classification of Tumors. 2nd ed. Berlin: Springer-Verlag; 1993.
3. Poulsgard L, Ronne M, Schmidek HH. The cytogenetic and molecular genetic analysis of meningiomas. In: Levine AJ, Schmidek HH, editors. Molecular genetics of nervous system tumors. New York: Wiley-Liss; 1993. p 249-254.
4. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-521.
5. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800.
6. Peyrard M, Fransson I, Xie Y-G, et al. Characterization of a new member of the human β-adaptin gene family from chromosome 22q12, a candidate meningioma gene. Hum Mol Genet 1994;3:1393-1399.
7. Lekanne Deprez RH, Riegman PHJ, Groen NA, et al. Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Oncogene 1995;10:1521-1528.
8. Rempel SA, Schwechheimer K, Davis RL, Cavenee WK, Rosenblum ML. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res 1993;53:2386-2392.
9. Bello MJ, de Campos JM, Kusak ME, et al. Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 1994;9:295-298.
10. Lindblom A, Ruttledge M, Collins VP, Nordenskjöld M, Dumanski JP. Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer 1994;56:354-357.
11. Simon M, von Deimling A, Larson JL, et al. Allelic losses on chromosome 14, 10, and 1 in atypical and malignant meningiomas: A genetic model of meningioma progression. Cancer Res 1995;55:4696-4701.
12. Rasio D, Murakumo Y, Robbins D, et al. Characterization of the human homologue of RAD54: A gene located on chromosome 1p32 at a region of high loss of heterozygosity in breast tumors. Cancer Res 1997;57:2378-2383.
13. Pitot HC, Goldsworthy T, Moran S. The natural history of carcinogenesis: Implications of experimental carcinogenesis in the genesis of human cancer. Journal of Supramolecular and Structural Cellular Biochemistry 1981;17:133-146.
14. Game JC. DNA double strand breaks and the RAD50-RAD57 genes in Sacharomyces. Cancer Biology 1993;4:73-83.
15. Thaler DS, Sctahl FW. DNA double-chain breaks in recombination of phage I and of yeast. Annu Rev Genet 1988;22:169-197.
16. Leone PE, Bello MJ, de Campos JM, et al. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene, in press.
17. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
18. Leone PE, Bello MJ, Mendiola M, et al. Six novel mutations in the NF2 tumor suppressor gene, Int J Oncol 1998;12:935-938.
19. Rey JA, Bello MJ, Jimenez A, et al. Loss of heterozygosity for distal markers of 22q in human gliomas. Int J Cancer 1992;51:703-706.
20. Bender B, Wiestler OD, von Deimling A. A device for processing large acrylamide gels. Biotechniques 1994;16:204-206.
21. Canzian F, Salovaara R, Hemminki A, et al. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 1996;56:3331-3337.
22. Mertens F, Johansson B, Höglund M, Mitelman F. Chromosomal imbalance maps of malignant solid tumors: A cytogenetic survey of 3185 neoplasms. Cancer Res 1997;57:2765-2780.
23. Mitelman F, Mertens F, Johansson B. A breakpoint of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 1997;15:417-474.
24. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash K. Human xeroderma pigmentosum group D genes encodes a DNA helicase. Nature 1993;365:852-855.
25. Ellis NA, Groden J, Ye TZ, et al. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 1995;83: 655-666.
26. Yu CE, Oshima J, Fu YH, et al. Positional cloning of the Werner's syndrome gene. Science 1996;272:258-262.
27. de Wind N, Dekker M, Berns A, Radman M, Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination and predisposition to cancer. Cell 1995;82:321-330.
28. Reitmair AH, Schmits R, Ewel A, et al. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 1995;11:64-70.
29. Reitmair AH, Redston M, Cai JC, et al. Spontaneous intestinal carcinomas and skin neoplasms in MSH2-deficient mice. Cancer Res 1996;56:3842-3849.
30. Bezzubova O, Silbergleit A, Yamaguchi-Iwai Y, Takeda S, Buerstedde JM. Reduced X-ray resistance and homologous frequencies in a RAD54-/- mutant of the chicken DT40 cell line. Cell 1997;89:185-193.
31. Wu W-J, Kakehi Y, Habuci T, et al. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res 1995;86:730-736.
32. Jin X, Wu X, Roth JA, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 1995;16:2205-2208.
33. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997;17:79-83.
34. Redston M, Nathanson KL, Yuan ZQ, et al. The APC I1307K allele and breast cancer risk. Nat Genet 1998;20:13-14.
35. Woodage T, King SM, Wacholder S, et al. The APC I1307K allele and cancer risk in a community-based study of Askenazi Jews. Nat Genet 1998;20:62-65.